Phase 1/2 Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) in Patients With BRAF-mutant Cancer Including Advanced Melanoma

Trial Profile

Phase 1/2 Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) in Patients With BRAF-mutant Cancer Including Advanced Melanoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2016

At a glance

  • Drugs Sonolisib (Primary) ; Vemurafenib
  • Indications Cancer; Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cascadian Therapeutics
  • Most Recent Events

    • 18 May 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 25 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 21 May 2013 Patients are currently being enrolled in the phase I dose escalation part of this trial according to the Oncothyreon Q1 2013 financial report.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top